Growth hormone release during sleep in growth-retarded children with normal response to pharmacological tests. 1978

E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi

Twenty-one prepubertal children of small stature, 10 boys and 11 girls, aged from 4-3 to 12-8 years, were studied. Their height was less than 3rd centile, and during the preceding year all had a growth rate less than 4-5 cm/year. Arginine and L-dopa tests were given, and the release of growth hormone (GH) during monitored sleep was investigated. On the basis of the electroencephalogram and horizontal electro-oculogram, sleep was divided into stages 1-2-3-4 and rapid-eye-movement. All the children had a GH response greater than 8 ng/ml in at least one of the two pharmacological tests, and were therefore accepted as not suffering from GH deficiency. In all 21 children during sleep there was at least one secretory peak with GH greater than 8 ng/ml. Of a total of 46 secretory peaks recorded, 22 (48%) took place during deep, slow sleep (stages 3-4), 10 (22%) during light sleep (stage 2), 10 (22%) during REM sleep, and 4 (8%) during wakening. In 4 patients (19%) no secretory peak was observed during stages 3-4, even though there were peaks at other times. The data (a) show that it is essential to monitor GH throughout the night to ascertain with certainty the presence or absence of physiological secretory peaks of GH; (b) emphasise the rare disagreement between pharmacological and physiological tests; (c) suggest the use of this physiological test for GH secretion in those cases where the insulin test may be hazardous.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D001846 Bone Development The growth and development of bones from fetus to adult. It includes two principal mechanisms of bone growth: growth in length of long bones at the epiphyseal cartilages and growth in thickness by depositing new bone (OSTEOGENESIS) with the actions of OSTEOBLASTS and OSTEOCLASTS. Bone Growth
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006130 Growth Disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth. Stunted Growth,Stunting,Disorder, Growth,Growth Disorder,Growth, Stunted,Stuntings
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001120 Arginine An essential amino acid that is physiologically active in the L-form. Arginine Hydrochloride,Arginine, L-Isomer,DL-Arginine Acetate, Monohydrate,L-Arginine,Arginine, L Isomer,DL Arginine Acetate, Monohydrate,Hydrochloride, Arginine,L Arginine,L-Isomer Arginine,Monohydrate DL-Arginine Acetate
D012890 Sleep A readily reversible suspension of sensorimotor interaction with the environment, usually associated with recumbency and immobility. Sleep Habits,Sleeping Habit,Sleeping Habits,Habit, Sleep,Habit, Sleeping,Habits, Sleep,Habits, Sleeping,Sleep Habit

Related Publications

E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi
July 1973, Archives of disease in childhood,
E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi
January 1985, Hormone research,
E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi
July 1990, The Journal of clinical endocrinology and metabolism,
E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi
December 1971, Pediatrics,
E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi
February 1992, Journal of endocrinological investigation,
E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi
May 1991, European journal of pediatrics,
E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi
January 1994, Medicina,
E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi
June 2008, Journal of endocrinological investigation,
E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi
December 1998, European journal of endocrinology,
E Cacciari, and G Coccagna, and A Cicognani, and P Pirazzoli, and R Gallassi, and P Farneti, and F Bernardi, and F Zappulla, and G Gobbi, and P Verucchi
November 1989, Pediatric research,
Copied contents to your clipboard!